Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

This study found that despite only topical minoxidil and oral finasteride being approved for androgenetic alopecia in Spain, dermatologists commonly prescribe various off-label treatments for both male and female patients.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This article discusses the characteristics of lichen planus pigmentosus and frontal fibrosing alopecia but reports no new clinical findings; the authors review existing knowledge.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

In this study, researchers found that combining fractional CO2 laser sessions with topical dutasteride was more effective in improving male androgenic alopecia than using the laser treatment alone, as observed through global photo assessments and dermoscopic parameters.

Dutasteride may become the top choice for treating hair loss.

In this study, researchers assessed the physical-chemical and microbiological stability of various pharmaceutical ingredients in the vehicle TrichoSolTM, finding differing beyond-use dates for the compounds, such as 180 days for cetirizine hydrochloride, but only 90 days for progesterone at higher concentrations.

Finasteride and dutasteride do not significantly change beard thickness in men.

Dutasteride injections can help treat hair loss in men and women.

Male hair loss is mainly due to thinner hair, not less hair.

Treatments for hair loss vary, but cell-based options may be the future.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.